Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Melanoma 37Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Neoplasms 9Colorectal Neoplasms 9Thyroid Carcinoma, Anaplastic 8Neoplasm Metastasis 6Multiple Myeloma 5Glioma 5Pancreatic Neoplasms 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Recurrence 3Prostatic Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Hematologic Neoplasms 3Ameloblastoma 3Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibroma, Plexiform 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Breast Neoplasms 2Astrocytoma 2

Interventions

AZD 6244 4trametinib 2cabozantinib 2Imatinib Mesylate 2pirfenidone 1peginterferon alfa-2b 1nilotinib 1binimetinib 1Vinblastine 1Methotrexate 1Liquid Biopsy 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neurofibroma, Plexiform × trametinib × Clear all
NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

St. Justine's Hospital

Phase 2 Active not recruiting
114 enrolled
CNS

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03741101 2024-04-11

plexifpc

Region Skane

Phase 2 Unknown
15 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡